vardenafil (levitra) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA PubChem repoDB

Active Ingredient History

NOW
  • Now
Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.   NCATS

Chemistry

  • SMILES: CCCc1nc(C)c2C(=O)N=C(Nn12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC)CC4
  • InChIKey: SECKRCOLJRRGGV-UHFFFAOYSA-N
  • Mol. Mass: 488.61
  • ALogP: 2.07
  • ChEMBL Molecules:
    vardenafil  
    vardenafil hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$11.6954 - $13.5852

United States

$13.9448 - $50.7290
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1h)-one | levitra | staxyn | vardenafil | vardénafil | vardenafil dihydrochloride | vardenafil hcl | vardenafil hydrochloride | vardenafil hydrochloride hydrate | vardenafil hydrochloride trihydrate | vardenafilum | vivanza

Organizations (41)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Erectile Dysfunction

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Brain Neoplasms (Early Phase 1)

Cystic Fibrosis (Phase 2)

Depression (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Endothelial Cells (Phase 4)

Erectile Dysfunction (Phase 4)

Fibrosis (Phase 4)

Genetic Diseases, Inborn (Phase 1)

Glioma (Early Phase 1)

Healthy Volunteers (Phase 1)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 3)

Hypogonadism (Phase 4)

Metabolic Syndrome (Phase 4)

Neoplasm Metastasis (Early Phase 1)

Pharmacokinetics (Phase 1)

Prostatic Hyperplasia (Phase 2)

Pulmonary Arterial Hypertension (Phase 4)

Raynaud Disease (Phase 2/Phase 3)

Reperfusion Injury (Phase 1)

Safety (Phase 4)

Sexual Dysfunction, Physiological (Phase 4)

Spinal Cord Injuries (Phase 4)

Tinnitus (Phase 2)

Urinary Bladder (Phase 2)

Urinary Bladder, Overactive (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 71
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue